Trial reportFrontiers in immunology2019
Acute Graft-vs.-Host Disease-Associated Endothelial Activation
Trial report in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Guideline
- A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy.Frontiers in immunology · 2022Pooled it
- Trial
- Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.Frontiers in immunology · 2026Article
- Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.Biomolecules · 2025Review
- The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies.Annals of hematology · 2024Review
- Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.Journal of cellular and molecular medicine · 2023Article
- Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro.Bone marrow transplantation · 2023Article
- Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.Journal for immunotherapy of cancer · 2023Article
- Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome.Frontiers in immunology · 2023Article
- Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications.Frontiers in medicine · 2023Review
- Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?Cardiovascular drugs and therapy · 2022Review
- An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct.Bone marrow transplantation · 2022Article
- Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication.Biochemical pharmacology · 2022Review
- Role of endothelial cells in graft-versus-host disease.Frontiers in immunology · 2022Review
- The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae.Bone marrow transplantation · 2021Review
- The microbiome-the revealing of a long time unbeknownst factor for outcome in murine models of graft-versus-host disease.Bone marrow transplantation · 2021Review
- Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2021Review
- Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy.Frontiers in immunology · 2021Article
- The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium.Bone marrow transplantation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis and endothelial activation and dysfunction have been associated with acute graft-vs.-host disease (aGVHD), pointing to the endothelium as a potential target for pharmacological intervention. Defibrotide (DF) is a drug with an endothelium-protective effect that has been approved for the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Clinical data suggest that DF also reduces the incidence of aGVHD; however, the mechanisms of DF-mediated aGVHD regulation have not been examined. To investigate possible DF-mediated prophylactic and therapeutic mechanisms in aGVHD, we performed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.